WAYNE, Pa., Feb. 12, 2014 /PRNewswire/ -- Ryan &
Maniskas, LLP is investigating potential claims against the board
of directors of Cadence Pharmaceuticals Inc. ("Cadence" or the
"Company") (NASDAQ: CADX) concerning possible breaches of fiduciary
duty and other violations of law related to the Company's efforts
to sell the Company to Mallinckrodt plc in a transaction valued at
approximately $1.3 billion.
(Logo: http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
)
If you own shares of Cadence and would like to learn more about
this class action or if you wish to discuss these matters and have
any questions concerning this announcement or your rights, contact
Richard A. Maniskas, Esquire
toll-free at (877) 316-3218 or to sign up online, visit:
www.rmclasslaw.com/cases/cadx. You may also email Mr.
Maniskas at rmaniskas@rmclasslaw.com.
Under the terms of the agreement, public shareholders of Cadence
will receive $14.00 per share in cash
for each share of Cadence they own.
Our investigation concerns possible breaches of fiduciary duty
and other violations of state law by Cadence's Board of Directors
for not acting in the Company's shareholders' best interests in
connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation
firm. Ryan & Maniskas, LLP is devoted to protecting the
interests of individual and institutional investors in shareholder
actions in state and federal courts nationwide. To learn more
about the class action process, please visit:
www.rmclasslaw.com.
CONTACT: Ryan & Maniskas,
LLP
Richard
A. Maniskas,
Esquire
995
Old Eagle School Rd., Suite
311
Wayne,
PA
19087
877-316-3218
www.rmclasslaw.com/cases/cadx
rmaniskas@rmclasslaw.com
SOURCE Ryan & Maniskas, LLP